Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Antiabortion-Rights Group Operation Rescue Considering Purchase Of Tiller's Clinic
Operation Rescue President Troy Newman on Wednesday said that his group is considering trying to purchase murdered abortion provider George Tiller"s Wichita, Kan., clinic, which Tiller"s family permanently closed on Tuesday, the New York Times reports. The clinic is owned by Tiller"s family. The family"s lawyer, Dan Monnat, called Operation Rescue"s proposal "just another irreverent, extremist publicity stunt." He declined to comment further on the situation. The family has not announced its plans for the building and land, which are worth $734,100, according to Sedgwick County, Kan., property records. The clinic has long been a focal point for the antiabortion-rights movement because it was one of the few in the U.S. that offered abortion later in pregnancy. Newman said that he has discussed the possible purchase with only a few members of Operation Rescue"s board but is certain that the funds could be raised if they decide to attempt to buy the clinic. Newman also said that one possibility for the location would be to turn it into a memorial museum to serve as "a tribute to the babies." He denied the claim that his comments are a publicity stunt.According to the Times, the closing of Tiller"s clinic has set off a "flurry of concerns" from abortion-rights advocates that it will be more difficult for women to access abortion services in situations when catastrophic health issues are identified late in pregnancy (Davey, New York Times, 6/11). LeRoy Carhart, a Nebraska abortion provider who worked with Tiller at the clinic, said that he will continue to perform third-trimester abortions in Kansas but did not provide information on where he will practice, the AP/Yahoo! News reports. Although he did not provide details, Carhart said that "there will be a place in Kansas for the later second- and the medically indicated third-trimester patients very soon." He said he has seen an increase in patients at his Nebraska clinic since Tiller"s murder. Carhart traveled to Tiller"s clinic to perform second- and third-trimester abortions because Kansas has less restrictive abortion laws than Nebraska. Carhart said he has not performed any procedures at his clinic after 22 weeks" gestation because his staff is not trained to do them. According to the AP/Yahoo! News, Nebraska law prohibits abortion when a fetus is considered viable. Kansas law, however, allows abortion after 21 weeks" gestation if continuing the pregnancy would endanger the woman"s life or cause "substantial and irreversible impairment" of a major bodily function, which courts have interpreted to include mental health (Gibbs, AP/Yahoo! News, 6/11).Broadcast CoverageThree media outlets on Wednesday reported on issues related to Tiller"s murder. Summaries appear below.~ MSNBC"s "The Rachel Maddow Show": The program included a discussion with Jennifer Boulanger, executive director for the Allentown Women"s Center, about threats to the center since Tiller"s murder (Maddow, "The Rachel Maddow Show," MSNBC, 6/10).~ NPR"s "All Things Considered": The program included a discussion with NPR health policy correspondent Julie Rovner about the correct terminology for referring to abortion later in pregnancy and why the phrase "late-term abortion" is inaccurate (Block, "All Things Considered," NPR, 6/10).~ WBUR"s "On Point": The program included a discussion with the Rev. Katherine Ragsdale -- a board member of NARAL Pro-Choice America and the incoming dean and president of Episcopal Divinity School -- and Jim Wallis -- founder and editor of the progressive evangelical group Sojourners -- about abortion-rights supporters" reaction to violence in the antiabortion-rights movement (Ashbrook, "On Point," WBUR, 6/10).

Future Of Independent Sector Treatment Centres, UK
The future use of Independent Sector Treatment Centres (ISTCs) in the NHS, will be fairer and on the same terms as other providers of NHS services, Health Minister Mike O"Brien announced today.
News of the day
American Medical Association Commits To Help Slow Increases In Health Spending
"The need for health reform that provides coverage and high quality, affordable health care for all Americans is clear. Rising health-care costs strain individual, business and government budgets, and projected increases in health spending are not sustainable. The AMA is committed to action to help achieve greater value from our nation"s health-care spending. We want to help bend the spending curve and move forward on health reform.
Nutrition

Massague: "We Have Discovered The First Genes Intervening In Brain Metastasis"

Joan Massagué (Barcelona, Spain, 1953) is the first winner of the BBVA Foundation Frontiers of Knowledge Awards in the Biomedicine category. The Frontiers of Knowledge Awards are intended to recognize and promote research of excellence. The breadth of disciplines addressed and their monetary amount a combined purse of 3.2 million euros spread over eight prize categories place them among the world"s foremost award schemes. Massagué is Spain"s most widely cited working scientist, with his papers referred to on more than 62,000 occasions. His studies, with great potential for clinical application, are opening up fundamental new pathways in the fight against cancer. He has conducted pioneering research into the genetic and cellular bases of metastasis and remains an acknowledged leader in this field. His group"s latest findings, published in the May edition of Nature, explain how tumor cells manage to enter the brain and form a new tumor. Until now, scientists were baffled as to how cancer cells were able to breach the blood-brain barrier which normally protects the brain from harmful substances. Massagué has identified three genes that intervene in the process, but the list will go on and work will continue to determine which is most important in each type of cancer. Research into the genes involved in cerebral metastasis and their mode of action, "is still very much at the preliminary stage", says Massagué. "These are the first brain metastasis genes to be identified, with clinical data". Dr. Massague"s team is engaged in other research to ascertain how breast cancer cells survive from the time they leave the primary tumor and infiltrate vital organs to the time when, years later, they start to grow uncontrollably and form macrometastases. In the view of the Frontiers laureate, it is during these latent years that metastasis cells may be most vulnerable. The focus of this research was breast cancer. And his team are now investigating whether the same genes may intervene in metastasis to other organs and in other types of cancer. In fact two have been verified in earlier studies as participating in breast cancer metastasis to the lungs. Precisely another of Massague"s major projects focuses on lung cancer metastasis, one of the biggest causes of cancer death. So far, his team has discovered the mechanisms whereby lung tumors invade the bones and the brain. Aside from the above work, conducted at the Memorial Sloan-Kettering Cancer Center in New York, Massagué is collaborating on various projects on breast and bowel cancer, led by Roger Gomis and Eduard Batlle, at the IRB (Institute for Biomedical Research) in Barcelona. Their focus is on how metastases develop, with potential application further ahead in new drug development or by clinical research teams. "The golden age of cancer research" Research into metastasis is all-important, since this process whereby a tumor colonizes other organs is responsible for 90% of cancer-related deaths. So what is the current state of knowledge in this area? "We are just starting to explore the dark forest that is metastasis. But my group and others have begun to cut a path, and there are reasons to believe that we will shortly have an accurate map". But his optimism is tinged with caution: "We have entered the golden era of cancer research, when we stand a good chance of understanding the genetic and environmental causes of this disease and improving its prevention and treatment," Massagué affirms. "Yet we must humbly recognize that this fight will take decades to produce an acceptable victory". Each research advance opens new avenues for obtaining more effective pharmaceutical therapies. Joan Massagué"s program, for instance, combines basic science with "translational" research, to ensure that the knowledge gained in the laboratory works through as quickly as possible to clinical practice. Massagué has this to say about the applied side of his work: "More than ever science permeates our everyday life. Biomedicine, at least, is a subject of great public interest and growing public understanding. Scientists respond to this demand by looking for faster ways to translate basic discoveries into practical knowledge with the power to solve health problems." Hence the succinct phrase the scientist employs to express his research motivation: "To uncover the unknown for the service of mankind". Massagué has over 340 publications to his name in leading scientific journals. He heads the Cancer Biology and Genetics Program at the Sloan-Kettering Institute, where he has pursued most of his scientific career. He is also a researcher at the Howard Hughes Medical Institute and adjunct director of the Institute for Biomedical Research (IRB Barcelona). His professional life, in other words, is a constant "shuttling between New York and Barcelona". Among the milestones in his scientific career was the isolating of TGF-Ãÿ (transforming growth factor beta), a group of molecules segregated by tumor cells that make normal cells behave like cancer cells. We now know that TGF-Ãÿ is the principle inhibitor of cell growth. It is essential for the organism"s normal development but, when disrupted, is also implicated in disease processes such as malformations and cancer. Massagué and his group identified the molecular pathway conveying the TGF-Ãÿ signal from the cell membrane to the nucleus rather like decoding the language it uses to communicate with other molecules and in this way have helped to elucidate one of the fundamental processes controlling cell division. Award presentation ceremony The presentation ceremony will take place on June 18 in the BBVA Foundation"s Madrid headquarters under the presidency of the Minister of Science and Innovation, Cristina Garmendia, and the BBVA Foundation President, Francisco González. The event will welcome eminent members of the international scientific community and high-level government institutions alongside personalities from the worlds of business and the arts. The Foundation is partnered in these awards by the Spanish National Research Council (CSIC), whose advisory input was instrumental in the appointment of the prize juries. The jury in the Biomedicine category was formed by Torsten Wiesel, Nobel Prize in Medicine; Angelika Schnieke, of the Technical University of Munich (Germany); Bruce Whitelaw, an expert in transgenic animals from the Roslin Institute (United Kingdom); Dario Alessi, of the Scottish Institute for Cell Signalling (United Kingdom); Robin Lovell-Badge, of the National Institute for Medical Research (United Kingdom); Josep Baselga, oncologist in the Hospital Vall d"Hebron Research Institute in Barcelona; and Juan Modolell of the Severo Ochoa Molecular Biology Center in Madrid, holder of the Santiago RamÃön y Cajal Research Prize in Biology. The BBVA Foundation supports knowledge generation, scientific research and the promotion of culture, relaying the results of its work to society at large. This effort materializes in research projects, human capital investment, specialization courses, grants and awards. Among the Foundation"s preferred areas of activity are basic sciences, biomedicine, ecology and conservation biology, the social sciences and literary and musical creation. BBVA Foundation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009